A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
We haven't written up this one. Inc. has the full story — the link below goes straight to it.